<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02159950</url>
  </required_header>
  <id_info>
    <org_study_id>I 250813</org_study_id>
    <secondary_id>NCI-2014-01184</secondary_id>
    <secondary_id>I 250813</secondary_id>
    <secondary_id>P30CA016056</secondary_id>
    <nct_id>NCT02159950</nct_id>
  </id_info>
  <brief_title>Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer</brief_title>
  <official_title>A Phase II Randomized Open Label Study of Sipuleucel-T vs. Sipuleucel-T and Tasquinimod in Patients With Metastatic Castrate-Resistant Prostate Cancer (CRPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Active Biotech AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well sipuleucel-T with or without tasquinimod
      works in treating patients with hormone-resistant prostate cancer that has spread to other
      parts of the body. Vaccines made from a person's tumor cells and white blood cells may help
      the body build an effective immune response to kill tumor cells. Tasquinimod may stop the
      growth of prostate cancer by blocking the growth of new blood vessels necessary for tumor
      growth. It is not yet known whether sipuleucel-T is more effective with or without
      tasquinimod in treating prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine whether tasquinimod augments immune response to sipuleucel-T.

      SECONDARY OBJECTIVES:

      I. To assess the safety and tolerability of the combination of sipuleucel-T and tasquinimod
      in patients with castration-resistant metastatic prostate cancer.

      II. To obtain preliminary evidence of the clinical benefit of the combination of sipuleucel-T
      and tasquinimod; to include changes in prostate specific antigen (PSA) over time, and
      duration of progression-free survival/overall survival.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive sipuleucel-T intravenously (IV) over 60 minutes on day 4. Treatment
      repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable
      toxicity.

      ARM II: Patients receive tasquinimod orally (PO) once daily (QD) beginning on day -14 and
      sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in
      the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod
      treatment after day 42 until disease progression.

      After completion of study treatment, patients are followed up every 3 months for up to 3
      years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Immune Response Assessed by IFN-g ELISPOT Specific for PA2024</measure>
    <time_frame>Baseline up to 50 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PSA Response</measure>
    <time_frame>Baseline to up to 3 years</time_frame>
    <description>PSA doubling time, PSA slope</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of PSA Response</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Toxicities Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The frequency of participants with toxicities will be tabulated by grade across all dose levels and courses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response</measure>
    <time_frame>Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response</measure>
    <time_frame>Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response (Arm 2 Only)</measure>
    <time_frame>Week 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rates (Partial or Complete)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA Progression</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Effects of Tasquinimod on the Inhibition of Immune Cells</measure>
    <time_frame>Up to week 50</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Hormone-Resistant Prostate Cancer</condition>
  <condition>Metastatic Prostate Carcinoma</condition>
  <condition>Recurrent Prostate Carcinoma</condition>
  <condition>Stage IV Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (sipuleucel-T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (tasquinimod, sipuleucel-T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (sipuleucel-T)</arm_group_label>
    <arm_group_label>Arm II (tasquinimod, sipuleucel-T)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sipuleucel-T</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (sipuleucel-T)</arm_group_label>
    <arm_group_label>Arm II (tasquinimod, sipuleucel-T)</arm_group_label>
    <other_name>APC8015</other_name>
    <other_name>APC8015 Vaccine</other_name>
    <other_name>PA2024 (PAP/GM-CSF)-Loaded Dendritic Cell Vaccine</other_name>
    <other_name>Provenge</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tasquinimod</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (tasquinimod, sipuleucel-T)</arm_group_label>
    <other_name>ABR-215050</other_name>
    <other_name>TASQ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic asymptomatic or minimally symptomatic castration-resistant prostate cancer
             (CRPC) patients who are eligible for sipuleucel-T

          -  Disease progression by PSA criteria (PSA Working Group Consensus Criteria Eligibility)
             and/or Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria

          -  Life expectancy &gt;= 6 months

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Hemoglobin &gt;= 100 g/L (&gt;= 10 g/dL)

          -  Leukocytes &gt;= 3,000/mm^3

          -  Absolute neutrophil count &gt;= 1,500/mm^3

          -  Platelets &gt;= 100,000/mm^3

          -  Total bilirubin =&lt; 1.5 x laboratory upper limit of normal

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =&lt; 2.5 x laboratory upper limit of normal

          -  Creatinine =&lt; 1.5 x laboratory upper limit of normal or calculated creatinine
             clearance of &gt;= 50 mL/min (please use institutional formula)

          -  Prothrombin time (PT)/international normalized ratio (INR) =&lt; 1.5

          -  Urine protein &lt; 1+; if &gt;= 1+, 24 hour urine protein should be obtained and should be &lt;
             1000 mg

          -  Central nervous system (CNS): no recent history (within 6 month) of cerebrovascular
             accident, transient ischemic attacks, central nervous system or brain metastases

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Patient verbalizes the ability to swallow and retain oral medication

          -  Subject or legal representative must understand the investigational nature of this
             study and sign an Independent Ethics Committee/Institutional Review Board approved
             written informed consent form prior to receiving any study related procedure

        Exclusion Criteria:

          -  Patients who have received systemic steroids within 4 weeks prior to starting study
             treatment

          -  Patients who have received prior immunotherapies

          -  History of therapy for an autoimmune disorder

          -  Patients receiving any other investigational agents

          -  Any medical condition that would preclude adequate evaluation of the safety and
             toxicity of the study combination

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure (New York Association class II, III,
             or IV), angina pectoris requiring nitrate therapy, recent myocardial infarction (less
             than the last 6 months), cardiac arrhythmia, history of cerebrovascular accident (CVA)
             within 6 months; no uncontrolled hypertension (defined as blood pressure of &gt; 160/90
             mmHg) on medication or, history of peripheral vascular disease

          -  Ongoing treatment with warfarin unless the international normalized ratio (INR) is
             well controlled and below 4

          -  History of psychiatric illness or social situations that would limit compliance with
             study requirements

          -  History of pancreatitis

          -  Human immunodeficiency virus (HIV)-positive patients receiving combination
             antiretroviral therapy are ineligible

          -  Systemic exposure to ketoconazole or other strong cytochrome P450, family 3, subfamily
             A, polypeptide 4 (CYP3A4) isoenzyme inhibitors or inducers within 14 days prior to the
             start of study treatment; systemic exposure to aminodarone is not allowed within 1
             year prior to the start of study treatment

          -  Ongoing treatment with sensitive cytochrome P450, family 1, subfamily A, polypeptide 2
             (CYP1A2) substrate or CYP1A2 substrate with narrow therapeutic range at the start of
             study treatment

          -  Ongoing treatment with CYP3A4 substrate with narrow therapeutic range at the start of
             study treatment

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to day 1 of therapy

          -  Unwilling or unable to follow protocol requirements

          -  Any condition which in the investigator's opinion deems the patient an unsuitable
             candidate to receive study drug
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saby George</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2014</study_first_submitted>
  <study_first_submitted_qc>June 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2014</study_first_posted>
  <results_first_submitted>February 10, 2016</results_first_submitted>
  <results_first_submitted_qc>April 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 20, 2016</results_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Sipuleucel-T)</title>
          <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
          <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV
Tasquinimod: Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All treated and eligible patients</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Sipuleucel-T)</title>
          <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
          <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV
Tasquinimod: Given PO</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="75.4" spread=".70"/>
                    <measurement group_id="B3" value="75.4" spread=".70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Immune Response Assessed by IFN-g ELISPOT Specific for PA2024</title>
        <time_frame>Baseline up to 50 weeks</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Immune Response Assessed by IFN-g ELISPOT Specific for PA2024</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in PSA Response</title>
        <description>PSA doubling time, PSA slope</description>
        <time_frame>Baseline to up to 3 years</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PSA Response</title>
          <description>PSA doubling time, PSA slope</description>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of PSA Response</title>
        <time_frame>Up to 3 years</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of PSA Response</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Toxicities Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4</title>
        <description>The frequency of participants with toxicities will be tabulated by grade across all dose levels and courses.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>All treated and eligible patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Toxicities Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4</title>
          <description>The frequency of participants with toxicities will be tabulated by grade across all dose levels and courses.</description>
          <population>All treated and eligible patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Response</title>
        <time_frame>Week 6</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Response</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Response</title>
        <time_frame>Week 10</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Response</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Response</title>
        <time_frame>Week 26</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Response</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Response</title>
        <time_frame>Week 50</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Response</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Response (Arm 2 Only)</title>
        <time_frame>Week 0</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Response (Arm 2 Only)</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rates (Partial or Complete)</title>
        <time_frame>Up to 3 years</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rates (Partial or Complete)</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>Up to 3 years</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>Up to 3 years</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PSA Progression</title>
        <time_frame>Up to 3 years</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PSA Progression</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effects of Tasquinimod on the Inhibition of Immune Cells</title>
        <time_frame>Up to week 50</time_frame>
        <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Sipuleucel-T)</title>
            <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
            <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV
Tasquinimod: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Tasquinimod on the Inhibition of Immune Cells</title>
          <population>Due a Lack of funding data was not collected and no patients were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Sipuleucel-T)</title>
          <description>Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Tasquinimod, Sipuleucel-T)</title>
          <description>Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
Laboratory Biomarker Analysis: Correlative studies
Sipuleucel-T: Given IV
Tasquinimod: Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="8" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="23" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="30" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="10" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="57" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="27" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="18" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="8" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="13" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="24" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the study's early closure, as a result of lack of funding, target accrual was not reached and no statistical inference of the primary and secondary aims were carried forth.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Administrator, Compliance - Clinical Research Services</name_or_title>
      <organization>Roswell Park Cancer Institute</organization>
      <phone>716-845-2300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

